Department of Surgery, Oncology, Gastroenterology, University of Padua, 35121 Padua, Italy.
Gastroenterology Unit, Azienda Ospedale-Università Padova, 35128 Padua, Italy.
Nutrients. 2024 Jan 26;16(3):370. doi: 10.3390/nu16030370.
The low FODMAP (fermentable oligosaccharide, disaccharide, monosaccharide, and polyol) diet is a beneficial therapeutic approach for patients with irritable bowel syndrome (IBS). However, how the low FODMAP diet works is still not completely understood. These mechanisms encompass not only traditionally known factors such as luminal distension induced by gas and water but also recent evidence on the role of FOMAPs in the modulation of visceral hypersensitivity, increases in intestinal permeability, the induction of microbiota changes, and the production of short-chain fatty acids (SCFAs), as well as metabolomics and alterations in motility. Although most of the supporting evidence is of low quality, recent trials have confirmed its effectiveness, even though the majority of the evidence pertains only to the restriction phase and its effectiveness in relieving abdominal bloating and pain. This review examines potential pathophysiological mechanisms and provides an overview of the existing evidence on the effectiveness of the low FODMAP diet across various IBS subtypes. Key considerations for its use include the challenges and disadvantages associated with its practical implementation, including the need for professional guidance, variations in individual responses, concerns related to microbiota, nutritional deficiencies, the development of constipation, the necessity of excluding an eating disorder before commencing the diet, and the scarcity of long-term data. Despite its recognized efficacy in symptom management, acknowledging these limitations becomes imperative for a nuanced comprehension of the role of a low FODMAP diet in managing IBS. By investigating its potential mechanisms and evidence across IBS subtypes and addressing emerging modulations alongside limitations, this review aims to serve as a valuable resource for healthcare practitioners, researchers, and patients navigating the intricate landscape of IBS.
低 FODMAP(可发酵寡糖、双糖、单糖和多元醇)饮食是治疗肠易激综合征(IBS)患者的有益方法。然而,低 FODMAP 饮食的作用机制尚不完全清楚。这些机制不仅包括传统上已知的因素,如气体和水引起的腔扩张,还包括最近关于 FOMAP 在调节内脏敏感性、增加肠通透性、诱导微生物群变化和产生短链脂肪酸(SCFAs)方面作用的证据,以及代谢组学和运动改变。尽管大多数支持证据质量较低,但最近的试验已经证实了其有效性,尽管大多数证据仅涉及限制阶段及其缓解腹胀和腹痛的有效性。这篇综述检查了潜在的病理生理机制,并概述了低 FODMAP 饮食在各种 IBS 亚型中的有效性的现有证据。使用它的关键考虑因素包括与其实践实施相关的挑战和缺点,包括对专业指导的需求、个体反应的差异、与微生物群相关的担忧、营养缺乏、便秘的发展、在开始饮食前排除饮食失调的必要性,以及长期数据的缺乏。尽管其在症状管理方面得到了公认的疗效,但承认这些局限性对于细致理解低 FODMAP 饮食在管理 IBS 中的作用至关重要。通过研究其在不同 IBS 亚型中的潜在机制和证据,并解决新出现的调节问题以及局限性,本综述旨在为医疗保健从业者、研究人员和患者提供有价值的资源,帮助他们在复杂的 IBS 领域中导航。